Allogene (NASDAQ: ALLO) insider files to sell 35,700 shares
Filing Impact
Filing Sentiment
Form Type
144
Rhea-AI Filing Summary
Allogene Therapeutics insider Zachary Roberts has filed a Form 144 notice to sell 35,700 shares of common stock, with an aggregate market value of $63,353.22, through Morgan Stanley Smith Barney on NASDAQ around February 2, 2026.
The shares were acquired on January 31, 2026 via restricted stock vesting under a registered compensation plan, with 224,730,144 common shares outstanding. In the prior three months, Roberts sold 26,269 common shares for gross proceeds of $40,979.64. The filer represents they are not aware of undisclosed material adverse information about Allogene.
Positive
- None.
Negative
- None.
FAQ
What does the Allogene (ALLO) Form 144 filed by Zachary Roberts disclose?
The Form 144 shows Zachary Roberts plans to sell 35,700 Allogene common shares on NASDAQ, valued at about $63,353.22. The shares came from restricted stock vesting under a registered compensation plan on January 31, 2026.
What prior Allogene (ALLO) stock sales by Zachary Roberts are reported?
Over the past three months, Zachary Roberts sold 26,269 Allogene common shares for gross proceeds of $40,979.64. This historical sale information is required in the Form 144 to show recent selling activity by the same person.
Which broker and exchange are used for this Allogene (ALLO) Form 144 sale?
The planned sale will be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ exchange. The Form 144 lists the broker’s New York address and an approximate sale date of February 2, 2026.
What representation does the seller make in the Allogene (ALLO) Form 144?
By signing the notice, the seller represents they do not know any material adverse information about Allogene’s current or prospective operations that has not been publicly disclosed, as required for sales relying on Rule 144.